What is multiple myeloma?

Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell in your bone marrow. These cancerous cells crowd out healthy blood cells and can damage bones, kidneys, and other organs. It's the second most common blood cancer in adults. While treatments have improved significantly in recent years, there's still a need for more effective options for patients whose cancer returns or doesn't respond to initial treatments.

What are bispecific antibodies like Lynozyfic?

Bispecific antibodies are engineered proteins that can bind to two different targets at the same time. In cancer treatment, they typically work by connecting cancer cells to immune cells (usually T cells). This brings the immune cells close to the cancer cells and activates them to attack. Lynozyfic and similar drugs target a protein called BCMA found on myeloma cells, while simultaneously engaging T cells, essentially creating a bridge that helps the immune system recognize and destroy the cancer.

What is CAR-T cell therapy?

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a type of treatment that takes a patient's own immune cells and modifies them in a lab to better recognize and fight cancer. Scientists add a special receptor (the CAR) to these T cells that helps them find specific proteins on cancer cells. The modified cells are then returned to the patient's body where they can multiply and attack the cancer. For multiple myeloma, many CAR-T therapies target the BCMA protein, similar to bispecific antibodies, but using a different approach.

Why do cancer drugs have such high pricing power?

Cancer drugs, especially breakthrough treatments, command high prices for several reasons. First, they address serious, life-threatening conditions with significant unmet medical needs. Second, developing these drugs requires enormous investment in research, clinical trials, and specialized manufacturing. For blood cancer therapies like those for multiple myeloma, the complex technologies involved (like engineered antibodies or cell therapies) add to costs. Additionally, these treatments often deliver remarkable results for patients who have few other options, which healthcare systems and insurers are willing to pay for because of the value they provide.

What does "BCMA-targeted" mean in cancer treatment?

BCMA (B-cell maturation antigen) is a protein found primarily on plasma cells and especially on multiple myeloma cells. When treatments are described as "BCMA-targeted," it means they're designed to specifically recognize and bind to this protein. This targeting approach helps the treatments distinguish cancer cells from healthy cells, potentially reducing side effects while effectively attacking the cancer. Many of the newest multiple myeloma therapies, including bispecific antibodies and CAR-T cell therapies, use BCMA as their target, making it a central focus in current blood cancer research.

16 handpicked stocks

Next-Gen Multiple Myeloma Treatments

Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.

Han Tan | Market Analyst

Published on July 3

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

Regeneron Pharmaceuticals, Inc.

REGN

Current price

$745.77

The catalyst company whose FDA approval for its bispecific antibody Lynozyfic validates the market for advanced multiple myeloma therapies.

Johnson & Johnson

JNJ

Current price

$241.52

A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therap...

A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therapy.

Pfizer Inc.

PFE

Current price

$26.61

A key competitor with its approved BCMAxCD3 bispecific antibody, Elrexfio, for patients with relapsed or refractory multiple myeloma.

Bristol-Myers Squibb Co.

BMY

Current price

$59.08

Legend Biotech Corp

LEGN

Current price

$18.75

GSK PLC-SPON ADR.

GSK

Current price

$53.39

Join Nemo FREE today and unlock every stock.

It only takes 60 seconds.

Your Basket's Financial Footprint

Market capitalisation breakdown for the Next-Gen Multiple Myeloma Treatments basket.

Key Takeaways for Investors:

Large-cap dominance suggests lower volatility and closer tracking to broad market performance, likely offering more stable returns.
Use as a core portfolio holding for diversified exposure, not as a speculative small-cap growth bet.
Expect steady, long-term capital appreciation rather than rapid, short-term explosive gains.

Total Market Cap

REGN: $61.40B
JNJ: $462.30B
PFE: $141.29B
Other

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.

If you invested across these assets:

≈

In 12 months it might be worth:

$1,000.00

+50.89%

≈

About This Group of Stocks

Our Expert Thinking

The FDA's approval of new bispecific antibodies for multiple myeloma has created a watershed moment for cancer treatment innovation. This validation opens doors for companies developing similar groundbreaking therapies that can command premium pricing while addressing critical patient needs.

What You Need to Know

This collection includes research-intensive biopharmaceutical companies focused on next-generation cancer treatments. These stocks represent a growth-oriented investment in biotechnology innovation, with companies ranging from established pharmaceutical giants to specialized biotech firms.

Why These Stocks

Each company was selected based on their direct involvement in developing advanced treatments for multiple myeloma. They're either pioneers who've received recent approvals, direct competitors with similar technologies, or key enablers of bispecific antibody and CAR-T therapies.

Group Performance Snapshot

50.89%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 50.89% over the next year.

13 of 15

Stocks Rated Buy by Analysts

13 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

💊

Breakthrough Cancer Treatments

These companies are developing therapies that could transform survival rates for blood cancer patients. Recent FDA approvals validate both the technology and massive market potential.

💰

Premium Pricing Power

Advanced cancer treatments command high prices due to their life-extending benefits. Companies with approved therapies for late-stage cancers can generate substantial revenue even with relatively small patient populations.

🔬

Scientific Innovation Leaders

This group includes pioneers in immunotherapy technologies that go beyond traditional treatments. Their innovations could potentially expand to other cancer types, multiplying their market opportunities.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Brazilian Diesel Shock | Which Stocks May Benefit?

Petrobras is raising diesel prices for the first time in over a year amid global oil volatility, prompting immediate government intervention through subsidies and tax cuts. This creates a unique investment landscape where agile fuel distributors, regional energy players, and agricultural firms can potentially capitalize on the shifting Brazilian market.

Streaming Profitability | Ad-Tech Infrastructure Play

Amazon is increasing the cost of its ad-free Prime Video tier by nearly 70 percent, reflecting a widespread push to boost streaming profitability. This shift toward premium add-ons and ad-supported base plans creates a strong outlook for major entertainment networks and digital advertising platforms.

Pharma Manufacturing | What's Next After TrumpRx

GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.

Next-Gen Multiple Myeloma Treatments

Top Picks from This Group

Your Basket's Financial Footprint

12 Month Growth Potential

About This Group of Stocks

Our Expert Thinking

What You Need to Know

Why These Stocks